Day: September 17, 2020

President Greg Peters to Present September 23, 2020Boca Raton, FL, Sept. 17, 2020 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCQB: BMTM), an end-to-end digital media and advertising services platform, today announced that management will present at the Proactive Disruptive Growth Forum on September 23, 2020.Greg Peters, President and Chief Operating Officer of Bright Mountain Media, is scheduled to host a virtual presentation during the 1-hour event as follows:Proactive Disruptive Growth ForumDate: Wednesday, September 23, 2020Time: 1:00 p.m. Eastern timeWebcast: https://www.proactiveinvestors.com/register/event_details/275The presentation is available for public viewing at the webcast link above. For more information on the Proactive Disruptive Growth Forum, please contact a Proactive representative.About Bright Mountain...

SALT LAKE CITY, Sept. 17, 2020 (GLOBE NEWSWIRE) — Overstock.com, Inc. (NASDAQ:OSTK), a leading ecommerce home furnishings retailer, recently opened a new fulfillment center in Fontana, California, in partnership with UPS Supply Chain Services. The new fulfillment center further aligns Overstock’s logistical footprint with key customers, significantly improving shipping speed, providing more accurate delivery estimates as well as a quicker port to warehouse process.“This California fulfillment center positions us to provide a better delivery process to our customers,” said Ron Hilton, Chief Sourcing and Operations Officer at Overstock.com. “Its close proximity to major ports, as well as its centralized location in one of our largest markets made Fontana ideal to create a more efficient bridge between our suppliers and our customers....

— FDA sets PDUFA goal date of July 7, 2021 —MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User Fee Act (PDUFA) goal date for the avacopan NDA. Avacopan is a first-in-class, orally administered therapy that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis.In its NDA acceptance letter, the FDA also indicated that it may, but has not yet determined whether to hold an advisory committee meeting to discuss the application per guidelines for...

BERKELEY HEIGHTS, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) — CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Paulo F. Costa to its Board of Directors.“We are excited to welcome Paulo to the CorMedix Board,” said Khoso Baluch, Chief Executive Officer of CorMedix. “Paulo will be a tremendous asset to our Board given his decades of leadership experience in the pharmaceutical sector and significant strategic experience gained in part during his time spent as Chairman of Amylin Pharmaceuticals through its successful sale to BMS and AstraZeneca. His experience at all levels of the business will prove invaluable as CorMedix progresses to the next stage of...

Shenzhen, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announces that the Company will host its earnings conference call on Friday, September 25, 2020 at 8:00 am Eastern Time (5:00 am Pacific Time/ 8:00 pm Beijing Time) to discuss the Company’s financial results of the second quarter ended June 30, 2020.To attend this earnings conference call, please use the information below for either dial-in access or webcast access. When prompted, please reference “Aesthetic Medical International Holdings Group Limited”Please dial in at least 15 minutes before the commencement of the call to ensure timely participation. For those unable to participate, an audio replay of the conference call will...

SCOTTSDALE, Ariz., Sept. 17, 2020 (GLOBE NEWSWIRE) — Meritage Homes Corporation (NYSE: MTH), a leading U.S. homebuilder, today announced that Steven J. Hilton, co-founder, chairman and chief executive officer of the Company, will be retiring as CEO effective January 1, 2021, but will continue to provide guidance and oversight in his role as the executive chairman of Meritage’s board of directors. Phillippe Lord, currently chief operating officer of Meritage Homes, has been appointed to serve as CEO upon Hilton’s retirement.Mr. Hilton has served as chairman and CEO since co-founding the Company in 1985. Meritage Homes is currently celebrating its 35th anniversary under Hilton’s leadership and has grown from a local startup in Scottsdale, Arizona to its current position as one of the largest and most respected national public homebuilders...

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) — via NetworkNewsWire— Kaival Brands Innovations Group Inc. (OTCQB: KAVL) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.To view the full publication, “Vaping Emerges from a Cloud,” please visit: http://nnw.fm/8ryJSWith the global e-cigarette and vape market expected to exceed $59 billion by 2027, the vaping industry appears to have weathered a cloud of scrutiny and is emerging better regulated and even stronger. Much of that growth stems from an increasing awareness of the advantages of consuming smokeless and ashless nicotine, backed up with growing studies.Although larger tobacco companies control a...

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to evaluate rilzabrutinib in IgG4-related disease (RD). “IgG4-RD is a serious fibro-inflammatory disease that can affect nearly any organ. The disease has long been under-diagnosed and under-treated, so we believe there is a significant medical need to have fast acting steroid free treatments with persistent responses. We believe rilzabrutinib has the potential to lead to positive outcomes in IgG4-RD by impacting many of the driving effector cells of the disease, including inflammatory monocytes, macrophages, eosinophils, B cells, IgG4+ plasmablasts...